Romidepsin

Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that several abstracts covering preclinical work with romidepsin will be presented at the 2007 Annual Meeting of the American Association of Cancer Rese...

Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that encouraging data from a preclinical study examining the combination of romidepsin and erlotinib in non-small cell lung cancer (NSCLC) cell lines de...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced that data for romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) were presented at the Ameri...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

...roaches poster session on Monday, April 16th in the Exhibit Hall, Poster Section 23 on Poster Board #9 -- "The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association with NF-.B inac...

Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma

...r the design of its registration-directed trial of romidepsin in patients with PTCL, and that it has received Or... drugs, histone deacetylase inhibitors, we believe romidepsin has significant potential as a treatment for a var... (approximately two years) from diagnosis. About romidepsin ...

Romidepsin in Biological News

Massey researchers induce cell death in leukemia

...ate director of translational research, interactions between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 fro...s synergistically with both agents to induce cell death in human CLL cells. romidepsin and belinostat are histone deacetylase (HDAC) inhibitors. "To the bes...